Arginase, a binuclear manganese metalloenzyme in the urea, catalyzes the hydrolysis of L-arginine to urea and L-ornithine. Both isoforms, arginase 1 and arginase 2 perform significant roles in the regulation of cellular functions in cardiovascular system, such as senescence, apoptosis, proliferation, inflammation, and autophagy, via a variety of mechanisms, including regulating L-arginine metabolism and activating multiple signal pathways. Furthermore, abnormal arginase activity contributes to the initiation and progression of a variety of CVDs. Therefore, targeting arginase may be a novel and promising approach for CVDs treatment. In this review, we give a comprehensive overview of the physiological and biological roles of arginase in a variety of CVDs, revealing the underlying mechanisms of arginase mediating vascular and cardiac function, as well as shedding light on the novel and promising therapeutic approaches for CVDs therapy in individuals.

**INTRODUCTION**

Cardiovascular diseases (CVDs) are the leading cause of death in all regions of the world. In 2019, the mortality rate associated with CVDs was nearly 17.9 million worldwide, representing 32% of all global death [1]. It is estimated that in 2030, deaths from CVDs will exceed 23 million [2]. Cardiovascular diseases, a collective term for cardiac and blood vessel diseases, conclude several conditions, such as hypertension, atherosclerosis, stroke, ischemic reperfusion injury and heart failure. Until now, a great deal of work has been performed to investigate the underlying mechanisms of cardiovascular diseases and corresponding therapeutic interventions. However, the mechanisms mediating the development and progression of CVDs remain incompletely understood.

Arginase, an ubiquitous metalloenzyme with L-arginine hydrolase activity, is capable of hydrolyzing L-arginine to form L-ornithine and urea, and regulating the formation of endothelium-derived vasodilator nitric oxide (NO) production by competing the substrate L-arginine with endothelial NO synthase (eNOS) [5]. More specifically, elevation of arginase activity may cause eNOS-uncoupling, that further leads to reduced NO production and increased formation of reactive oxygen species (ROS) [5]. The lack of NO and overproduced ROS play a key role in the progression of endothelial dysfunction [6], the hallmark of CVDs. Furthermore, arginase can regulate cellular functions including senescence, apoptosis, autophagy, proliferation, and inflammation in multiple cell types independently or dependently on its L-arginine hydrolase activity, which further results in the pathophysiological of several CVDs.

**FACTS**

- Arginase is associated with L-arginine metabolism, nitric oxide production, and multiple signal pathways dependently or independently of its L-arginine-urea hydrolase activity.
- Arginase regulating various cellular functions and processes (senescence, apoptosis, proliferation, inflammation, and autophagy) plays key roles in the pathogenesis of cardiovascular diseases, such as hypertension, atherosclerosis, stroke, ischemic reperfusion injury and heart failure.
- Arginase-mediated p38MAPK, mTOR, and p53 and other signaling pathways are involved in the impairment of several cellular functions during the progression of cardiovascular diseases (CVDs).
- Targeting arginase provides a huge research prospect for CVDs therapy.

**OPEN QUESTIONS**

- What are the exact molecular mechanisms that arginase regulates the cell senescence, apoptosis, proliferation, inflammation, and autophagy?
- What are the specific differences between ARG1 and ARG2 in various cells/tissues?
- Is it feasible to develop ARG1 and ARG2-specific inhibitors?
- What are the adverse effects of targeting arginase in CVDs?
In recent years, a vast body of evidence convincingly indicated that arginase is closely related to the development of CVDs in human beings, such as hypertension [7], atherosclerosis [8], diabetic vascular disease [9], ischemic reperfusion (IR) [10], and HF [11]. Furthermore, some small-molecular arginase inhibitors have been explored and clinically tested in hypertension, HF, IR, etc. Therefore, arginase was gradually regarded as a novel and promising therapeutic target for various CVDs. In this review, we summarize the features and functions of arginase, the roles of arginase in cells of vascular and cardiac system, as well as in the development of CVDs. Novel and promising therapeutic approaches that target arginase for CVDs treatment in individuals are also summarized in an effort to preserve cardiovascular health in the background of high global health burden on CVDs.

ARGINASE

Isoforms of arginase
Arginase, an ubiquitous metalloenzyme with L-arginine hydrolase activity, which had been found in bacteria, yeasts, plants, invertebrates, and vertebrates [12], plays a critical role in physiological and pathological conditions [13]. There are two isoforms of arginase: arginase 1 (ARG1), which is expressed in the cytosol, and arginase 2 (ARG2), which is mainly located in the mitochondria. Although there are approximately 60% homologous between the two isoforms, they show 100% homology in the critical areas for catalyzing function [14], and exhibit similar enzymatic activity. However, the two isoforms differ in their tissue distribution and physiological functions [5]. Both arginase isoforms were found in mammals, whereas most plants, bacteria, yeasts, and invertebrates only express ARG2 [13]. ARG1 is mainly expressed in the liver responsible for the urea cycle, and also found in a variety of extracellular tissues including cardiovascular system, red blood cells (RBCs), skin, specific immune cell populations, lung, and intestine [5, 15–18], whereas the specific functions of ARG1 in these tissues remain unknown. ARG2, on the other hand, is significantly expressed in the kidney and also widely expressed in some other organs like the brain and retina [13].

Functions: L-arginine metabolism
Arginase specifically catalyzes the conversion of the amino acid L-arginine to L-ornithine and urea to dispose of toxic ammonia in the final step of the urea cycle (Fig. 1) [19]. L-ornithine can be further metabolized by ornithine decarboxylase to small cationic molecules polyamines. Polyamines are involved in a variety of fundamental functions including cell proliferation, cell growth, and transport [20], or catalyzed by ornithine aminotransferase to form L-proline, which is essential for collagen formation [21]. Notably, L-arginine also serves as the sole nitrogen-containing endogenous substrate of the enzyme nitric oxide synthase (NOS), which specifically catalyzes the conversion of L-arginine to L-citrulline, nitric oxide, and reactive nitrogen intermediates, such as peroxynitrite [21]. It is well known that NO, an unorthodox messenger molecule, plays essential roles in many biological functions, especially in the circulatory system, such as vasodilation regulation, inhibition of platelet aggregation and adhesion, inhibition of leukocyte adhesion and vascular inflammation, and control of vascular smooth muscle proliferation [22]. Thus, L-arginine is also critical for maintaining endothelial function and preventing CVDs [23]. For example, supplementation of L-arginine reduces IR-induced endothelial dysfunction in patients with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) [24]. Yan et al. demonstrated that this supplementation can boost NO bioavailability through inducing higher expression and phosphorylation of eNOS [25]. Moreover, L-arginine has been shown to inhibit inflammatory activation and regulate redox homeostasis in interstitial aortic valve cells to suppress the pro-calcific differentiation [26]. Accordingly, L-arginine supplementation for prevention and treatment of cardiovascular disorders, such as hypertension, atherosclerosis, CAD, HF, and peripheral artery disease, are receiving widespread attention, although its clinical efficacy still remains debatable [23]. And those controversial results could be explained by asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NOS. It was reported that L-arginine level and L-arginine/ADMA ratio are positively related to endothelium-dependent vasodilation in resistance arteries [27], and L-arginine/ADMA ratio is now regarded as a crucial marker of NO bioavailability and risk factor of atherosclerosis [28].

In view of the importance of NO and L-arginine in endothelial function, the imbalance between arginase and NOS due to arginase upregulation can induce the overconsumption of L-arginine, provoking a lack of substrate for NOS to produce NO [19, 29], leading to endothelial dysfunction. Moreover, decreased bioavailability of L-arginine also induces NOS-uncoupling, which...
produces superoxide anion instead of NO, and the increased oxidative stress further exacerbates NO-uncoupling [5], and aggravates NO inactivation. Furthermore, ARG2 promotes Ca^{2+}-dependent eNOS phosphorylation through parkin-dependent p32 degradation [30]. As a result, an imbalanced increase in arginase in the cardiovascular system, particularly in ECs, will limit NO production and promote superoxide formation, eventually leading to vascular endothelial dysfunction.

**Arginase expression in cardiovascular system**

*Arginase expression in cardiac system.* Both ARG1 and ARG2 were reported to express in the cardiac system, including myocytes and nonmyocytes (Table 1). Jung et al. reported that both arginase isozenymes were detected in left ventricular (LV) crude homogenates, however, only ARG1 was present in isolated cardiac myocytes, which was downregulated in LV hypertrophy, and ARG2 was found in nonmyocytes [31]. Conversely, in rats, although both ARG1 and ARG2 were present in the whole heart, ARG2 alone was found in isolated myocytes [32], indicating that the cardiac arginase expression appears to be species- and tissue-dependent. Advanced studies in heart found that ARG1 expression can be induced by hypobaric hypoxia [33], and ARG2 was significantly upregulated in the aged cardiac tissue [11]. Arginase in cardiac myocytes is capable of inhibiting the inflammation response [34] and limiting NO as well as cGMP synthesis, hence regulating myocardial contractility [31]. Furthermore, arginase was also detected in the immune cells infiltrating in heart. For instance, both ARG1 and ARG2 were found in the polymorphonuclear cells in ischemic-reperfused myocardium [35], and ARG1 expression was observed in heart-infiltrated CD68+ macrophages [36]. Arginase appears to have a role in the control of the immune response in the heart and the development of cardiac disease [36].

**Arginase expression in vascular system.** Numerous studies proved that arginase is widely expressed in a variety of blood vessels, including the aorta [37], carotid [38], coronaries [39], gracilis muscle arterioles [40], pulmonary microvascular [41], pulmonary artery [42], and retinal microvascular (Table 1) [43]. Both isoforms of arginase can be detected in various ECs of different species, such as human pulmonary artery ECs [44], human umbilical vascular endothelial cells (HUVECs) [8, 45], bovine aortic ECs [46], rat and mouse aortic ECs [37, 47], coronary arteriolar ECs [39, 48] and so on. In ECs, expression of ARG1 can be stimulated by thrombin [47], oxidative species, NADPH oxidase 2 [49], and tumor necrosis factor-alpha (TNF-α) [48], while ARG2 can be regulated by hypoxia [50], ET-1 [51], oxidized low-density lipoprotein [52], oscillatory shear stress [53], and aging [54]. Both ARG1 and ARG2 in ECs have been demonstrated to be involved in the regulation of NO production and vasodilation [55, 56]. Arginase was also found to be present in VSMCs [57]. ARG1 from VSMCs can be activated by interleukin-4, interleukin-13 [58], transforming growth factor-β1 [59], and cyclic stretch [60]. The pro-inflammatory factors interleukin-13 [61], and hypoxia [42] can induce the expression of ARG2 in VSMCs.

**ARGINASE MEDIATES VARIOUS CELLULAR FUNCTIONS**

**Arginase in cellular senescence.** Cellular senescence, a state of permanent and irreversible cell-cycle arrest [62], is intimately linked to CVDs and was found in sick cardiovascular tissues [63]. Excessive arginase activity has been associated with EC senescence in aging humans and animals [64], and lowering arginase protein expression/activity reverses endothelial senescence [65, 66]. Overexpression of ARG1 can promote cell senescence indicated by upregulation of senescence markers p53-S15 and p21Wp1, and increased SA-β-gal positive cells in HUVECs (Fig. 2) [45]. Diabetes-induced premature senescence of retinal ECs was alleviated by inhibition of ARG1 [43]. Similarly, ARG2 was also found to be upregulated in senescent ECs compared to young cells, and its silencing suppressed the senescence markers such as SA-β-gal activity, p53-S15, and p21 [67]. Chronic L-arginine treatment accelerates EC senescence, which is also through upregulation of ARG2 [68]. The mechanism of arginase regulating endothelial senescence is believed to be related with the increase oxidative stress because of eNOS-uncoupling [45, 54, 67]. Further studies discovered that both ARG1 and ARG2 activated the mammalian target of rapamycin complex 1 (mTORC1)/S6 kinase 1 (S6K1) pathway which is an important regulator of organism aging. Moreover, ARG2 was also identified to form a positive circuit together with S6K1 and p38 mitogen-activated protein kinase (p38MAPK), contributing to endothelial senescence and cardiovascular aging through eNOS-uncoupling [54]. In VSMCs, arginase also exhibited pro-senescent function. Xiong et al. have reported that overexpression of ARG2 in VSMCs from human umbilical veins can initiate myocardial dysfunction, and finally lead to the senescence through a mechanism involving activation of p66Shc and p53 [69]. Additionally, ARG2 accelerates VSMC senescence through mTORC1-S6K1 activation, which is mediated by association of myo1b with lysosomes and lysosome redistribution [57]. Of note, these functions of ARG2 including activation of S6K1, p38MAPK, and p66Shc appear to be independent of its L-arginine-urea hydrolase activity, but rely on its C-terminal [57, 69]. Besides in the circular system, arginase was also widely found to involve in cell senescence in other systems. For example, overexpression of ARG2 in keratinocytes can enhance the expression of senescence-associated β-Gal [70]. ARG2 exacerbates nucleus pulposus cell senescence caused by oxidative stress and inflammation via the nuclear factor-κB pathway [71]. Importantly, disruption of ARG2 gene was shown to lengthen the longevity of mice [72]. Thus, the arginase may present a promising target to reverse vascular cell senescence, slow down the aging process and mitigate the development of CVDs. However, the specific mechanism of arginase regulating senescence still needs further study.

**Arginase in cell apoptosis.** Apoptosis is a type of programmed cell death that is distinct from necrosis [73]. Excessive cellular apoptosis in cardiovascular system may contribute to a fatal outcome [74]. Arginase has been reported to regulate apoptosis in various cells. In VSMCs, ARG2 can induce apoptosis due to mitochondrial dysfunction through a complex positive crosstalk among S6K1-c-Jun N-terminal kinase, extracellular-signal-regulated kinase, p66Shc, and p53, independently of its ureohydrolase activity (Fig. 2) [69]. Suwanpradit et al. demonstrated that ARG2 is associated with apoptosis of bovine retinal endothelial cells and vascular injury induced by hyperoxia, and inhibition of ARG2 activity can minimize apoptosis and ameliorate this scenario by preventing NOS uncoupling [75]. In the old wild-type mice, upregulated ARG2 is engaged in β-cell apoptosis by inducing the release of TNF-α from pancreatic acinar cells through p38MAPK [76]. In addition, arginase can also induce apoptosis through L-arginine deprivation and ROS production in some argininosuccinate synthase defective cells that cannot synthesize L-arginine [77]. Howarvitz and colleagues [78] reported that arginase can also induce apoptosis through L-arginine deprivation and ROS production in some argininosuccinate synthase defective cells that cannot synthesize L-arginine by themselves [77, 78]. However, there are still some contrary reports about the role of arginase in apoptosis. For example, ARG2 was reported to negatively regulate mercury-induced apoptosis in renal cells [79]. Moreover, upregulated ARG2 protein induced by inflammation can temper cytokine-induced apoptosis in intestinal epithelial cells through reducing NO production competitively, considering that excess NO production can lead to apoptosis [80]. Thus, the regulation of arginase on apoptosis likely depends on the cell type and its mechanism, and the function and mechanism of arginase in cardiovascular apoptosis still need further exploration.
Table 1. Expression and function of arginase in cardiovascular system.

| Type of cell | Arginase expression | Species/tissue/cell | Inducer or activator | Effect of arginase | Refs |
|--------------|---------------------|---------------------|----------------------|-------------------|------|
| Vascular system | ARG1 | Human coronary arterioles | Increased in diabetes | Reduce NO production and diminish vasodilation | [55] |
|  | | Mouse coronary arterioles | Increased by TNF-α | Lead to O$_2^-$ production and induce endothelial dysfunction in IR injury | [48] |
|  | | HUVEC | — | Promote endothelial senescence and inflammatory responses through eNOS-uncoupling | [45] |
|  | | BAEC | Increased by oxidative species through RhoA/Rho kinase pathway | — | [46] |
|  | | RAEC | Increased by thrombin | — | [47] |
|  | | MAEC | Increased in HFHS diet | Regulate obesity-induced vascular inflammation | [37] |
|  | | BREC | Induced by NOX2 | Induce premature EC senescence | [43] |
| ARG2 | HUVEC | — | Inhibit EC autophagy through MTOR and PRKAA/AMPK signaling | [8] |
| Rat coronary artery | ARG1 | HUVEC | Increased in diabetes | Impair coronary artery microvascular function | [39] |
|  | | HUVEC | Increased by ageing | Activate p38MAPK and S6K1; promote endothelial senescence | [54] |
|  | | Porcine carotid endothelial cell | Increased by exposure of arteries to OSS | Impair NO-dependent endothelial function | [53] |
|  | | Human carotid artery endothelial cell | Stimulated by ET-1 | Stimulate ROS formation in THP-1-derived macrophages | [51] |
|  | | HAECC | Activated by OxLDL through LOX-1 receptor and Rho/ROCK signaling | Downregulate NO, increase ROS, lead to EC dysfunction | [52] |
|  | | HPMVEC | Increased by hypoxia | Promote HPMVEC proliferation | [41] |
| VSMC | ARG1 | RASMC | — | Promote RASMC proliferation through polyamines production | [84] |
|  | | Human aortic | — | Suppresses TNF-α release, inhibit monocyte chemotaxis and migration, inhibit NO release from iNOS, attenuate atherosclerotic plaque inflammation | [181] |
| ARG2 | HPASMC | — | Promote HPASMCs proliferation | [42] |
|  | | HUVSMC | — | Promote VSMC senescence and apoptosis by activating mTORC1 through myo1b | [57] |
|  | | HPASMC | Increased by IL-13 | Induce HPASMCs proliferation and pulmonary vascular remodeling | [61] |
|  | | HPASMC | Increased by AMPK | Promote HPASMCs proliferation | [87] |
|  | | HUVSMC | — | Promote VSMC senescence and apoptosis through p66shc and p53 | [69] |
| Macrophage | ARG1 | — | Inhibited by Fra-1 | Inhibit inflammation in arthritis through fostering the transition of macrophages from a pro-inflammatory to an anti-inflammatory state | [93] |
|  | | — | Induced by lipoproteins | — | [92] |
| ARG2 | — | Induced by ET-1 | Promote ROS production | [51] |
|  | | — | — | Promote macrophage pro-inflammatory responses through mitochondrial reactive oxygen, result in arteriogenesis | [94] |
|  | | — | Increased by IL-10 | Enhance SDH activity, increase mitochondrial respiration, influence the inflammatory status of the macrophage | [182] |
| Cardiac system | Myocardial | Cat | Decreased in LVH | Regulate NO-dependent myocardial contractility | [31] |
|  | | Rat | Increased in ageing | Decrease age-related contractile function | [11] |
|  | | Rat | — | Regulate NO-dependent basal myocardial contractility in a NOS1-dependent manner. | [32] |
| Polymorphonuclear | ARG1; ARG2 | Pig | Increased in IR | — | [35] |

ARG1 arginase 1, ARG2 arginase 2, VSMC vascular smooth muscle cell, EC endothelial cell, NO nitric oxide, TNF-α tumor necrosis factor-α, IR ischemic reperfusion, eNOS endothelial NO synthase, HFHS high-fat/high-sucrose, NOX2 NADPH oxidase 2, p53 tumor suppressor p53, MTOR mammalian target of rapamycin, PRKAA/AMPK protein kinase AMP-activated α catalytic subunit, p38MAPK p38 mitogen-activated protein kinase, S6K1 ribosomal protein S6 kinase, OSS oscillatory shear stress, ET-1 Endothelin-1, OxLDL oxidized low-density lipoprotein, ROS reactive oxygen species, iNOS inducible nitric oxide synthase, mTORC1 mechanistic target of rapamycin complex 1, IL-13 interleukin-13, Fra-1 Fos-related antigen 1, IL-10 interleukin-10, SDH succinate dehydrogenase, LVH left ventricular hypertrophy, HUVEC human umbilical vein endothelial cell, BAEC bovine aortic endothelial cells, RAEC rat aortic endothelial cells, MAEC mouse aortic endothelial cell, HAECC human aortic endothelial cells, HPMVEC human pulmonary microvascular endothelial cells, HPASMC human pulmonary artery smooth muscle cell, HUVSMC human umbilical vein smooth muscle cell.
Arginase in cell proliferation

Cell proliferation is essential for the development of the organism and its organs [81]. Cardiovascular cell proliferation is critical for cardiovascular function and development [82]. As explained above, arginase is capable of converting L-arginine to L-ornithine which is further to form polyamines. Polyamines are necessary for cell proliferation. Complement factor B-induced upregulation of ARG1, p38MAPK, and S6K1 can accelerate vascular endothelial senescence through eNOS-uncoupling. ARG2 promotes myo1b association with lysosomes, induces lysosome re-distribution and TSC-lysosome dissociation, reliefs the inhibitory effect of TSC2 on the mTOR activator Rheb therefore activates mTORC1-S6K1 signaling, eventually leading to VSMC senescence. ARG2 promotes mitochondrial dysfunction by complex positive crosstalk among S6K1-JNK, ERK, p66Shc, and p53, leading to VSMC senescence and apoptosis. ARG2 can activate mTORC2, further activating AKT-mTORC1-S6K1 signaling and inhibiting AMPK, thereby impairing cellular autophagy. Besides, ARG2 can inhibit AMPK activation through TP53 signaling. ANG II angiotensin II, LPS lipopolysaccharide, OxLDL oxidized low-density lipoprotein, TNF-α tumor necrosis factor-alpha, CAD coronary artery disease, HC hypercholesterolemia, HT hypertension, IR ischemic reperfusion, VSMC vascular smooth muscle cell, EC endothelial cell, ARG1 arginase 1, ARG2 arginase 2, IL-6 interleukin-6, MCP-1 monocyte chemoattractant protein-1, ROS reactive oxygen species, p53 tumor suppressor p53, mTORC1 mechanistic target of rapamycin complex 1, myo1b myosin-1b, TSC tuberous sclerosis complex, ERK extracellular signal-regulated kinase, JNK c-Jun N-terminal kinase, TP53 tumor protein 53, AKT v-akt murine thymoma viral oncogene homolog 1, AMPK protein kinase AMP-activated α catalytic subunit, S6K1 ribosomal protein S6 kinase.

Arginase in cell proliferation

Cell proliferation is essential for the development of the organism and its organs [81]. Cardiovascular cell proliferation is critical for cardiovascular function and development [82]. As explained above, arginase is capable of converting L-arginine to L-ornithine which is further to form polyamines. Polyamines are necessary for cell proliferation. Complement factor B-induced upregulation of ARG1 can drive polyamine overproduction in macrophages, thereby leading to cardiac fibroblast (CF) proliferation and collagen production [83]. Elevated ARG1 has been shown to boost polyamine production in rat aortic smooth muscle cells, which speeds up VSMC proliferation and neointima formation (Fig. 2) [84]. Silencing ARG2 in senescent VSMCs can diminish proliferation, indicating that ARG2 may promote VSMC proliferation [69]. Decrease of ARG1 and ARG2 activity induced by limonin can prevent native low-density lipoprotein-induced VSMC proliferation in a p21Waf1/Cip1-dependent manner through inactivation of NADPH oxidase [85]. In addition, overexpression of either ARG1 or ARG2 can facilitate endothelial proliferation through polyamine synthesis, which is tightly linked to angiogenesis and wound healing [86]. Hypoxia has been reported to accelerate human pulmonary microvascular ECs proliferation via upregulation of ARG2 by epidermal growth factor–epidermal growth factor receptor–extracellular-signaling-regulated kinase pathway [41] and induce human pulmonary artery SMCs proliferation through arginase induction by AMPKα signaling [87]. On the other side, arginase’s enzymatic activity results in the consumption of L-arginine which is required in some types of cells, resulting in delayed growth and even death. Hepatic ischemia-reperfusion leads to substantial release of arginase and then deprives systemic L-arginine, which further inhibits the proliferation of brain microvascular endothelial cells by cell cycle arrest [88]. Overall, arginase is engaged in the regulation of cell proliferation and has significant implications for angiogenesis, vascular remodeling as well as cardiovascular functions.
Arginase in cellular inflammation

Inflammation is a natural defense mechanism of the body in response to harmful stimuli [89]. Chronic inflammation, is related to various CVDs, such as atherosclerosis, chronic HF, and myocardial infarction [90]. Due to inhibition of NO from iNOS by arginase, ARG1 is always considered as a classical anti-inflammatory marker in M2 macrophage and is capable of dampening the macrophage inflammatory response. It is reported that recombiant human ARG1 can inhibit the immune function in activated macrophages [91]. Moreover, the expression and activity of ARG1 in macrophages can be boosted by lipoproteins [92] and decreased by Fos-related antigen 1 [93]. Unlike the anti-inflammatory effects of ARG1, ARG2 appears to be more pro-inflammatory. Although ARG2 competes with iNOS to reduce NO, it is nonetheless linked to the M1 phenotype of macrophages. Ming et al. showed that overexpression of ARG2 in macrophages boosts pro-inflammatory cytokine production, such as TNF-α, interleukin-6 (IL-6), and monocyte chemotactant protein-1 expression by stimulating mitochondrial ROS generation (Fig. 2) [94]. Liu et al. also discovered that the release of TNF-α and IL-6 from bone marrow-derived macrophages of ARG2 knockout mice is lower than that of wild type [95]. Moreover, ARG2 also induces a pro-inflammatory phenotype in other cell types. For example, ARG2 is mediated in senescent ECs to induce expression of inflammatory vascular adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) [67], as well as the generation of pro-inflammatory cytokines such as IL-6 and interleukin-8 [54], which is through activation of p38MAPK and S6K1. Huang and colleagues reported that ARG2 promotes age-associated adipose tissue inflammation by inducing IL-6 production through p38MAPK [96]. In pancreatic acinar cells of aging mice, the upregulated ARG2 induces the paracrine release of inflammatory cytokine TNF-α through activating p38MAPK signaling [76]. The level of ARG2 expression in mice is upregulated in proximal tubular S3 segment cells with aging, then silencing ARG2 gene can decrease TNF-α-induced ICAM-1 and VCAM-1 level in the proximal epithelial cells [97]. Down-regulating arginase levels can attenuate the increase of inflammatory cytokines, such as TNF-α, IL-6, and interleukin-1β, which mitigates pneumonoperitoneum-induced inflammation [98]. Taken together, these data indicate that arginase plays a crucial role in cellular inflammation, but different isoforms of arginase may show different effects, which is most likely related to the activity-independent function of ARG2. Consequently, it will be an interesting challenge to further explore the mechanism of arginase regulating inflammation and its activity-independency effect, which will help to unravel the mystery.

Arginase in cellular autophagy

Autophagy, a major intracellular degradation system, is implicated in maintaining the healthy status of an organism under stress conditions [99]. A great deal of work has been performed to support a crucial role of autophagy in the regulation of intracellular homeostasis in most cells of cardiovascular origin [100]. In the heart, autophagy primarily serves as a pro-survival process during cellular stress, eliminating aggregated protein and damaged organelles. EC intrinsic autophagy regulates EC response to a variety of metabolic stresses and is important for redox homeostasis and EC plasticity, and is also involved in modulating other important functions, such as NO production, angiogenesis, and hemostasis/thrombosis [101]. Most recently, arginase has been discovered to play a role in autophagy control. In human ECs, ARG2 impairs cellular autophagy through activation of mTORC2, which further induces AKT-mTORC1-S6K1 signaling and inhibits AMPK, independently of its L-arginine-urea hydrolase activity (Fig. 2) [8]. Moreover, it was observed that recombiant human ARG1 downregulated autophagy in activated macrophages, and activation of autophagy alleviated recombinant human ARG1-induced immunosuppression [91]. In the mouse model of oxygen-induced retinopathy, ARG2 deletion prevents hyperoxia-induced retinal vascular injury, which is associated with activation of autophagy [102]. Additionally, upregulation of ARG2 inhibits autophagy in keratinocytes through stimulating cellular senescence [70]. Overall, maintaining optimal autophagy function by targeting arginase is a viable technique for CVDs treatment. However, the functions and regulation of arginase implicated in vascular autophagy are largely unknown, further investigations are needed to determine the mechanism of ARG1 or ARG2 in autophagy regulation.

ARGINASE CONTRIBUTES TO CVDS DEVELOPMENT

Arginase in hypertension

Hypertension is a well-known risk factor for various CVDs [103]. Arginase-induced endothelial dysfunction has been demonstrated to offer a vital mechanism in the development of hypertension. The age-dependent augment of arginase expression in vascular and plasma occurs before the initiation and progression of hypertension in obese rats, and treatment with an arginase inhibitor prevents the development of hypertension [104]. Subsequently, it was proved that arginase impairs vascular function in elderly spontaneously hypertensive rats via an NO-dependent mechanism (Fig. 3) [7]. In deoxycorticosterone acetate-salt hypertension, arginase is also involved in its pathogenesis, and both arginase isoforms contribute to vascular endothelial dysfunction, especially ARG1 that is upregulated in the aorta of rats with deoxycorticosterone acetate-salt hypertension and associated with the elevated systolic blood pressure (BP), impaired endothelium-dependent vasorelaxation and increased vasoreactivity to constrictor stimuli [105]. Additionally, it was reported that inhibiting arginase improved reflex vasodilatation in patients with hypertension [106], and prevented impaired NO production, and reduced ROS generation in aorta isolated from animals with metabolic syndrome [107]. A recent study reported that ARG2 upregulation activated by hypoxia contributes to a lower NO availability in hypoxia-induced hypertension [108]. In the hypoxia-induced PAH rat model, ARG1 and ARG2 expression were induced [109], and arginase inhibition can mitigate the increase of right ventricle systolic pressure and right ventricle hypertrophy via inhibiting HPASMC proliferation [110]. Similarly, arginase inhibition also decreases the right ventricle systolic pressure and mitigates the lung tissue remodeling in the monocrotaline-induced pulmonary hypertension rat model [111]. Taken together, targeting arginase may be a potential strategy for hypertension therapy and prevention. However, whether ARG1 and ARG2 differ in the development of hypertension warrants further investigation.

Arginase in atherosclerosis

Atherosclerosis is a common ailment that occurs when plaque builds up inside the arteries. Disease linked to atherosclerosis is the leading cause of death in the world. Endothelial dysfunction as a result of reduced NO bioavailability is a critical initial event in atherosclerosis. Arginase is frequently associated with endothelial dysfunction and further atherosclerosis. For example, Ryoo et al. reported that arginase activity is upregulated in vascular ECs of ApoE−/− mice after a high cholesterol diet, and further investigation revealed that ARG2 knockdown restores decreased vascular NO production, ameliorates endothelial function, and prevents increased vascular stiffness [112]. Importantly, activation of HDAC2 or PARP-1 inhibition is reported to attenuate atherogenesis both through reducing ARG2 expression, restoring NO production in ECs, and ultimately ameliorating vascular dysfunction [113, 114]. Independent of the NO mechanism, Xiong et al. found that ARG2 knockdown suppresses atherosclerotic lesion formation in ApoE−/− mice through rescuing autophagy [8]. Additionally, ARG2 was also demonstrated to affect atherosclerotic plaque instability and
muscle. Arginase expression and activation play a pivotal role in the rest of the body owning to weakness or stiffness of the heart in HF. Arginase in heart failure could be a promising therapeutic target for atherosclerosis. It plays a critical role in the pathogenesis of atherosclerosis, which is elevated atherosclerotic plaque stability [116]. However, Yi et al. showed that arginase inhibition is capable of ameliorating inflammation and inducing pro-inflammatory responses in macrophages (Fig. 3) [117]. These results imply that arginase, especially ARG2, plays a critical role in the pathogenesis of atherosclerosis, which could be a promising therapeutic target for atherosclerosis.

**Arginase in heart failure**

HF is defined as a problem with the heart’s ability to pump blood to the rest of the body owning to weakness or stiffness of the heart muscle [118]. Arginase expression and activation play a pivotal role in the development and progression of HF. Clinically, patients with HF are characterized by higher ARG1 expression compared to normal patients [118]. Further study indicated that patients with severe HF showed higher ARG1 expression compared with patients with mild HF, and arginase inhibition ameliorated microcirculation of patients with HF in a NO-dependent manner [118]. Moreover, upregulation of ARG1 stimulated by complement factor B can induce cardiac remodeling in the uremic mice model through causing CF proliferation and collagen production (Fig. 3). In contrast, arginase inhibition tempers cardiac remodeling in uremic mice [83].

A recent study also showed increased ARG1 level in inflammatory cells from blood and heart leads to poor L-arginine bioavailability to eNOS, which might be the reason for HF with preserved ejection fraction in obese ZSF1 rats [119]. Heusch et al. observed that in the rabbit model of pacing-induced HF, ARG2 is significantly upregulated in cardiac and further promotes iNOS uncoupling and superoxide anions production, which may lead to contractile dysfunction [120]. In the doxorubicin-induced cardiomyopathy mice model, arginase inhibition can promote NO release from aortic ECs and macrophages, decrease the afterload for LV, and eventually ameliorate LV systolic function [121]. Collectively, upregulated arginase plays a causal role in the distinct etiologies of HF, thus arginase may be a potential target for HF treatment.

**Arginase in IR injury**

Myocardial IR injury contributes to poor cardiovascular outcomes after myocardial ischemia, cardiac surgery, or circulatory arrest. Accumulating evidence has demonstrated a causal role for arginase in IR injury in vitro and in vivo. In vitro investigation indicated that upregulation of ARG2 in bovine retinal ECs induces mitochondrial dysfunction and fragmentation, increases EC stress, and reduces cell survival, ultimately promoting IR-induced vascular injury, while the specific knockdown of ARG2 in EC of IR mice model with injury in the right eye attenuates IR-induced retinal detachment/edema and reduces impairment of the blood-retinal barrier [56]. In the myocardium and aorta of IR rats, arginase expression is significantly enhanced. Further study showed that vagal nerve stimulation can suppress the IR-induced arginase elevation through activating α7 nAChR, reduce the infarct size and mediate the cardio-protective effect [122]. Arginase reduction induced by ROCK inhibition can reduce infarct size in a NOS-dependent manner, further protecting the diabetic heart against IR injury in rats with type 1 diabetes [123]. Administration of RBCs with elevated arginase expression and activity from mice or patients with T2DM can impair post-ischemic cardiac recovery of nondiabetic hearts via provoking eNOS-derived ROS production in RBCs, while this result can be alleviated by inhibition of RBC arginase [124]. Kövamees et al. reported that arginase inhibition alleviates endothelial dysfunction after IR in patients with CAD [125]. Arginase expression is significantly enhanced in the myocardium of IR pig in comparison with the sham group, and further analysis indicated that arginase down-regulation is capable of inducing a decrease in infarct size via increasing NO bioavailability [35], implying that arginase plays a crucial role in the development in IR injury.

**Arginase in diabetic vascular disease**

Diabetes is frequently associated with numerous vascular pathologies, which may lead to obvious morbidity and mortality progression by promoting VSMC senescence and apoptosis [69] and inducing pro-inflammatory responses in macrophages (Fig. 3) [94]. In addition, in a late stage of human carotid plaques, ARG2 activation in ECs and macrophages can trigger ROS formation, which may further enhance atherosclerosis progression [51]. In contrast to ARG2, ARG1 upregulation has been reported to ameliorate atherosclerosis [115], manifested as dampening atherosclerotic plaque inflammation, increasing Th2 cytokine levels, and facilitating VSMC proliferation, ultimately leading to the elevated atherosclerotic plaque stability [116]. However, Yi et al. showed that arginase inhibition is capable of ameliorating endothelial function through enhancing NO production in ApoE−/− mice [117]. In the doxorubicin model, arginase inhibition can promote NO release from aortic ECs and inhibiting ROS production in RBCs, while this result can be alleviated by administration of RBCs with elevated arginase expression and activity from mice or patients with T2DM can impair post-ischemic cardiac recovery of nondiabetic hearts via provoking eNOS-derived ROS production in RBCs, while this result can be alleviated by inhibition of RBC arginase [124]. Kövamees et al. reported that arginase inhibition alleviates endothelial dysfunction after IR in patients with CAD [125]. Arginase expression is significantly enhanced in the myocardium of IR pig in comparison with the sham group, and further analysis indicated that arginase down-regulation is capable of inducing a decrease in infarct size via increasing NO bioavailability [35], implying that arginase plays a crucial role in the development in IR injury.
in diabetic patients [13]. Several experimental studies have demonstrated that arginase is a key factor driving cardiovascular complications in diabetic patients. Analysis of forearm blood flow in patients with T2DM showed that arginase inhibition can ameliorate endothelium-dependent vasorelaxation, which is maintained after glucose optimization [9]. ARG1 inhibition can ameliorate streptozocin-induced vascular dysfunction through increased NO production [126]. Studies of the retinal arterioles from diabetic pigs have shown that early type 1 diabetes can increase the arginase activity, thereby impairing endothelium-dependent NO-mediated dilation of retinal arterioles during diabetes, while arginase blockade leads to the opposite results [127]. Chandra et al. demonstrated that diabetes/hyperglycemic states can cause elevated arginase activation in aortic ECs through RhoA/ROCK/MAPK pathway [128]. Furthermore, Zhou et al. revealed that RBC ARG1 mediates endothelial dysfunction in T2DM. ARG1 expression and activity can be upregulated in RBCs from T2DM by a ROS-dependent mechanism, which leads to endothelial dysfunction in healthy arteries following co-incubation of T2DM RBCs and healthy arteries (Fig. 3) [129]. Further study demonstrated that RBCs peroxynitrite impairs endothelial function in T2DM via activating arginase in endothelial cells [130]. Recently, Li et al. illustrated that serum extracellular vesicle-derived ARG1 levels were significantly higher in T2DM patients compared with non-T2DM patients [131]. Elevated ARG1 in serum exosomes of diabetic mice can be delivered to ECS, which subsequently results in diabetic endothelial dysfunction via inhibiting NO synthesis [132]. Therefore, targeting arginase, especially ARG1 is a promising pharmacological tool to improve vascular function in diabetic patients.

Arginase in COVID-19 and its vascular complications

Currently, coronavirus disease 2019 (COVID-19) pandemic has led to a global healthcare crisis, and it can cause various systemic complications, including vascular and pulmonary diseases. COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which enters body through binding angiotensin-converting enzyme 2 (ACE2) that is abundantly expressed in human endothelial cells of the arterial and venous vessels. Thus, endothelial cells are considered as the main barrier against SARS-CoV-2 invasion, and endothelial dysfunction is proved to be a fundamental feature of COVID-19 and associated with COVID-19 complications [133]. For this, arginase is likely to be involved in COVID-19 and its vascular complications, since it induces endothelial dysfunction by depleting L-arginine and decreasing NO bioavailability. Derakhshani et al. reported that the expression of ARG1 was significantly increased in the whole blood of COVID-19 patients compared to healthy individuals, which might be a potential marker in the pathogenesis of COVID-19 and its complications [134]. Furthermore, large amount of ARG1+ MDSC cells was found in the lungs of patients who died from COVID-19 complications, which might deplete L-arginine, leading to impaired T cell receptor and endothelial function [135]. Additionally, numerous investigations based on metabolomics analysis identified lower L-arginine levels in plasma of patients with COVID-19, indicating an increase in arginase activity in these patients [136]. Another clinical study also discovered that circulating level of ADMA in COVID-19 patients is significantly higher, impairing the bioavailability of L-arginine [137]. Based on these, inhibition of arginase and/or replenishment of L-arginine is potential in preventing/treating severe COVID-19. A clinical trial discovered that oral L-arginine supplementation to standard therapy significantly shorten hospitalization of patients with severe COVID-19 [138]. Similarly, another group also indicated that combination of L-arginine and vitamin C shows beneficial effects on long-COVID symptoms [139]. Moreover, L-arginine might attenuate SARS-CoV-2 infection through other mechanisms, such as reducing binding of SARS-CoV-2 to ACE2, inhibiting transmembrane protease serine-type 2, and suppressing SARS-CoV-2 replication [133]. Collectively, targeting abnormal arginase expression and loss of L-arginine might be an effective strategy for prevention and treatment of COVID-19 and its mediated vascular impairment.

ARGINASE AS A TARGET FOR CVD THERAPY

Chemical arginase inhibitors

Some chemical compounds, such as N-hydroxy-L-arginine (NOHA) and its analogs N-hydroxy-nor-arginine (Nor-NOHA), 2(S)-amino-6-(borono)hexanoic acid (ABH), and S-(2-boronoethyl)-L-cysteine (BEC), were identified as arginase inhibitors which are now being attempted for the treatment of a variety of CVDs (Table 2).

NOHA is a stable intermediary of NO production by NOS and displays a weak competitive inhibition via interacting with the bimanganese cluster of the arginase. NOHA shows an inhibitory effect on human ARG1 with $K_r$ (pH 8.5) of 3.6 µM [140] and ARG2 with $K_r$ (pH 7.5) of 1.6 µM [141]. Inhibition of NOHA on ARG2 is 20 times more powerful than on ARG1 [141]. NOHA can restore NO-mediated coronary arteriolar dilation through decreasing inflammatory cells migration in IR mice [48]. Nor-NOHA, the derivative of NOHA, is also a quick-acting, potent, non-specific arginase inhibitor [142], shows an IC50 value on human ARG1 in 1.36 µM and human ARG2 in 1.26 µM [143]. Inhibition of nor-NOHA on ARG2 is 10 times stronger than on ARG1 [141]. Nor-NOHA appears to be one of the most potent inhibitors of ARG2 at physiologic pH [141]. The clinical trials of arginase inhibitors in CVDs treatment are under investigation with the use of nor-NOHA that has entered the phase 2 trials. Administration of Nor-NOHA protects from endothelial dysfunction following IR in patients with CAD (NCT02009527) [125] and ameliorates endothelium-dependent vasodilatation in patients with familial hypercholesterolemia [144] and T2DM (NCT02687152) [145]. Furthermore, nor-NOHA can rescue microcirculation of patients with HF [118] and temper CR in uremic mice [83]. Additionally, nor-NOHA is capable of attenuating the development of IR [146], hypertension [147], and atherosclerosis [148]. In particular, no apparent toxicity was present following 20 min [125] of intra-arterial infusion of nor-NOHA at a dose of 0.1 mg/min in CAD patients. And the oral bioavailability (F) of NOHA and nor-NOHA is sufficient, with F values of more than 50% [149]. Because of the hydroxyguanidine chemical and metabolic liability [149], nor-NOHA presents rapid elimination with $t_{1/2}$ of 30 min and can be rapidly cleared from the plasma in concordance [150].

ABH and BEC, two boronic amino acid derivatives, can bind to the active manganese site of arginase. ABH has proven to be a competitive slow binding inhibitor with submicromolar activity ($IC_50$ of 1.54 µM on human ARG1 and 2.55 µM on human ARG2) [151]. BEC is a cysteine-based ABH analogous (IC50 of 1.26 µM [143]). The clinical trials of arginase inhibitors in CVDs treatment attempted for the treatment of a variety of CVDs (Table 2).

| Chemical Name | IC50 | Clinical Trials |
|---------------|------|----------------|
| ABH           | 1.54 µM | - |
| BEC           | 2.55 µM | - |
| NOS           | 3.6 µM | - |
| Nor-NOHA      | 1.36 µM | - |
| Nor-NOHA      | 1.26 µM | - |
| NOHA          | 3.6 µM | - |
| Nor-NOHA      | 1.26 µM | - |


cell Death Discovery (2022) 8:413

Z. Li et al.
Table 2. The effects of arginase inhibitors against cardiovascular diseases.

| Arginase inhibitor | Diseases | Model | Dosage | Effect of arginase inhibition | Refs |
|--------------------|----------|-------|--------|-------------------------------|------|
| Chemical arginase inhibitors | | | | | |
| NOHA | IR injury | IR rat | 0.1 mmol/L | Decrease inflammatory cells migration in IR, prevent inflammatory cells invasion | [48] |
| Nor-NOHA | Cardiomyopathy | Doxorubicin-induced cardiomyopathy mice | 100 μmol/L, 12 h | Facilitate LV systolic function, lower tail BP and afterload for LV | [121] |
| PAH | Monocrotaline-induced PH rat | 100 mg/kg, 15 d | Reduce RVPs and lung tissue remodeling | [111] |
| Diabetic vascular disease | Retinal arterioles isolated from streptozocin-induced diabetic pigs | 0.1 mmol/L, 1.5 h | Improve dilution of retinal arterioles isolated from diabetic pigs | [127] |
| Diabetic vascular disease | Patients with T2DM | 0.1 mg/min, 2 h | Improve microvascular endothelial function | [145] |
| CAD | Patients with CAD | 0.1 mg/min, 20 mins | Improve flow-mediated dilatation after IR | [125] |
| Hypertension | Spontaneously hypertensive rats | 40 mg/day, 10 weeks | Reduce systolic BP, improve vascular function, reduce artery remodeling and cardiac fibrosis | [147] |
| Atherosclerosis | ApoE-/- mice | 10 mg/kg, 5 days/week, 9 weeks | Reduce the lipid deposition, vascular ROS, the number of macrophages and the size of atherosclerotic plaques | [148] |
| Natural arginase inhibitors | | | | | |
| Animo acids | Diabetic vascular disease | Patients with T2DM | 2000 mg/day, 1 month | Restore NO production levels | [161] |
| | Ischemic rats | Citrulline (50 mg/kg) or ornithine (200 mg/kg) | Reduce the gait scores, infarct volume and brain edema | [162] |
| | Streptozocin-induced diabetic rats | Citrulline (50 mg/kg) or ornithine (200 mg/kg) | Reduce the elevation in diastolic BP, increase NO generation, inhibit ROS generation, restore impairment in vasoconstriction response | [184] |
| | Hypertensive (SIAH strain) rats | Norvaline (30 mg/kg), 7 d | Reduce the BP | [163] |
| | Metabolic syndrome rats | Citrulline (50 mg/kg), norvaline (50 mg/kg) and ornithine (200 mg/kg) | Reduce ROS, increase NO, restore endothelial-dependent relaxation, reduce the BP | [107] |
| Polyphenols | Atherosclerosis | ApoE-KO mice | Pomegranate juice (31 mL/day, 10 weeks) | Promote a switch in macrophage phenotype from M1 pro-inflammatory to M2 anti-inflammatory state | [185] |
| | IR injury | IR rat | EPI (1 mg/kg, 10 d) | Reduce increased nNOS isofrom protein levels, maintain eNOS activity | [176] |
| | Hypertension | Old rat | PIC (30 mg/kg/day, 4 d) | Reduce BP, enhance NO production, recover endothelial dysfunction | [173] |

ABH 2(S)-amino-6-(borono)hexanoic acid, BECS S-(2-boronoethyl)-L-cysteine, NOHA N-hydroxy-L-arginine, Nor-NOHA N-hydroxy-nor-arginine, RSV resveratrol, PIC piceatannol, EPI (-)-Epicatechin, IR ischemic reperfusion, LV left ventricle, RVPs right ventricular systolic pressure, T2DM type 2 diabetes mellitus, CAD coronary artery disease, BP blood pressure, ROS reactive oxygen species, HPASMCHuman pulmonary artery smooth muscle cell, NO nitric oxide, ApoE-KO apolipoprotein E deficient, ApoE-/- apolipoprotein E-null, nNOS neuronal NO synthase, eNOS endothelial NO synthase, PH pulmonary hypertension.
A variety of amino acids have been proved to be weak inhibitors for arginase with IC50 values in the millimolar range [158]. Of that, L-ornithine presents the highest inhibitory efficiency (with 60% of inhibition at 20 mM and Ki of 1.02 mM on bovine arginase) by competing with substrate L-arginine on the active sites, and L-citrulline is working as an allosteric inhibitor of arginase with 53% of inhibition at 20 mM [159, 160], while norvaline is a non-competitive inhibitor of the arginase enzyme. Currently, clinical trials are underway to evaluate L-citrulline as a single candidate for the treatment of vascular endothelial dysfunction. One clinical study reported that taking L-citrulline supplements completely prevented the increase of arginase activity, and restored NO production levels in T2DM patients [NCT03358264] [161]. L-citrulline and L-ornithine also present protective effects in ischemic brain damage [162]. Intraperitoneal injection with L-norvaline for 7 days in rats with hypertension presents higher renal L-arginine level but has no significant effect on the blood concentration of amino acids [163]. Furthermore, amino acids are capable of keeping on minimum side effects that could arise from the use of chemical compounds [164].

Polyphenols, including resveratrol (RSV), picatanol (PIC), and (-)-Epicatechin (EPI) perform ARG1 and ARG2 inhibitory activity, which have been investigated for CVDs treatment. RSV, shows arginase inhibitory activity, with inhibition of 38.7 ± 3.1% on liver ARG1 and 32.0 ± 1.3% on kidney ARG2 at 50 µmol/L [165]. RSV treatment can augment vessel constriction in deendothelialized aortas [165], prevent hypoxia-induced human pulmonary artery SMC proliferation, and normalize right ventricular hypertrophy in an in vivo neonatal rat model of pulmonary hypertension [166]. It has also been reported to exert cardioprotective and vasoprotective effects including antiatherosclerotic and vasorelaxation action [167]. However, high doses of RSV may cause cell death. Enhanced apoptosis was displayed in rat PASMC after intermediate concentrations of RSV (100 µM) [168]. In addition, only trace amounts have been observed following administration of an oral dose of 25 mg of RSV, with a peak value of 2 µmol/L in plasma and t1/2 of 9.2 h [169]. The oral absorption of RSV in humans is ~75%, but the bioavailability of RSV is relatively low, and oral bioavailability is less than 1% because of metabolism in the intestine and liver and its subsequent elimination [170]. PIC, an analog and metabolite of RSV [171], presents potential arginase inhibition with an inhibitor effect with IC50 of 12.1 µM on mammalian arginase [172]. PIC administration reduced the BP and recovered endothelial dysfunction in aged mice [173]. Whereas, the clinical use of PIC is restricted due to small solubility and poor bioavailability rather than medium absorption [174]. EPI has been reported to work as an competitive arginase inhibitor with moderate inhibitory effect (IC50 = 1.8 ± 0.5 µM) [175]. EPI is capable of reversing EC senescence [65] and exhibiting cardioprotective effects through maintaining eNOS activity in rat models of IR [176]. Although these polyphenols only display a moderate inhibitory effect on arginase and lack specificity, those plant-derived polyphenol compounds owning to the dihydroxyphenyl group still exhibit antioxidant activity and potential cardiovascular-protective function [177].

CONCLUSIONS AND FUTURE PERSPECTIVE

The overactivation of arginase is the key element in the initiation and development of various CVDs. Elevated arginase expression can impair several cellular functions through regulating L-arginine metabolism and various signaling pathways, such as p38MAPK, mTOR, and p53, contributing to vascular and cardiac pathological conditions and subsequent CVDs, indicating that targeting arginase may be a potential therapeutic approach for CVDs. Recently, an increasing number of arginase inhibitors have been developed for the prevention and treatment of CVDs. Whereas, there are still unresolved questions and challenges regarding translating preclinical findings into therapeutic applications. To begin with, despite extensive clinical and experimental research indicating the potential of arginase as a biomarker and diagnostic tool for the progression of CVDs, there is still no clinical definition standard for arginase activity or ARG1/2 expression levels in blood or tissues for CVDs diagnosis. Thus, an arginase prediction model or system based on deep learning of clinical data, including CVDs types, arginase activity/expression levels, patient information, and so on, is needed to assess CVD progression, considering that ARG1 in liver is responsible for urea-cycle and ARG2 in kidney is correlated with the urine-concentrating capability, the main risk of arginase inhibitor acting systemically might induce renal dysfunction and urea-cycle disturbance, which may cause hyperammonemia. Therefore, biological monitoring of plasma ammonia and urine orotic acid, as well as hepatic function biomarkers, would be essential. Furthermore, the global loss of ARG2 activity may contribute to the development of hypertension [178]. Thus, exploring ARG1- and ARG2-specific inhibitors must be investigated. However, no isofom-specific arginase inhibitor has been reported owing to the substantial similarity between ARG1 and ARG2. Inspiringly, emerging evidence has shown the crucial role of vaccines in cardiovascular disease, which can prevent CVDs onset and development through immunomodulation [179], and vaccines against ARG1 or ARG2 is already in preliminary trials for cancer treatment [180]. Whereas, neither ARG1 nor ARG2-targeting vaccines were reported in CVDs therapy until now. It is worth noting that ARG2 regulates vascular cell functions through mTOR, p66shc, and p53 signaling pathways independently of its L-arginine-urea hydrolase activity, implying that inhibiting the level of arginase expression may be a more effective approach for CVDs therapy. In addition, a number of arginase inhibitors, especially those containing boronic acid functionality may cause acute toxicity symptoms in human, such as nausea, vomiting, diarrhea, and lethargy [157]. Therefore, the effect of arginase inhibitors in larger clinical settings and the potential adverse effects of long-term arginase inhibitor treatment needs to be determined. Of note, some compounds isolated from natural medicinal plants can act as arginase inhibitors with hypotoxicity, which may provide a novel approach for arginase inhibition.

REFERENCES

1. WHO. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (2021).
2. Colantonio LD, Mintner T. Time for reducing global cardiovascular mortality. Circulation. 2019;140:726–8.
3. Dumor K, Shoemaker-Moyle M, Nistala R, Whaley-Connell A. Arterial stiffness in hypertension: an update. Curr Hypertens Rep. 2018;20:72.
4. Herrington W, Lacey B, Sherlik P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016;118:835–46.
5. Pernow J, Jung C. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc Res. 2013;98:334–43.
6. Mahdi A, Kovamees O, Pernow J. Improvement in endothelial function in cardiovascular disease—is arginase the target? Int J Cardiol. 2020;301:207–14.
7. Arishe O, McKenzie J, Priviero F, Eibeigbe AB, Webb RC. L-arginine induces vascular dysfunction in old spontaneously hypertensive rats. J Afr Assoc Physiol Sci. 2019;7:119–27.
8. Xiong YY, Yeperi G, Foribeth M, Yu Y, Montani JP, Yang ZH, et al. ARG2 impairs endothelial autophagy through regulation of mTOR and PRKA/MAPK signaling in advanced atherosclerosis. Autophagy. 2014;10:2223–38.
9. Mahdi A, Kovamees O, Checa A, Wheelock CE, von Heijne M, Alvansson M, et al. Arginase inhibition improves endothelial function in patients with type 2 diabetes mellitus despite intensive glucose-lowering therapy. J Intern Med. 2018;284:388–98.
10. Tengborn J, Cederström S, Verouhis D, Bohn F, Eriksson P, Folkersten L, et al. Arginase 1 is upregulated at admission in patients with ST-elevation myocardial infarction. J Intern Med. 2021;290:1061–70.
32. Steppan J, Ryoo S, Turcotte E, Bugaj L, et al. Upregulation of arginase-II contributes to decreased age-related myocardial contractile reserve. Eur J Appl Physiol. 2012;112:2933–41.

33. Dzik JM. Evolutionary roots of arginase expression and regulation. Front Immunol. 2014;5:544.

34. Caldwell RW, Rodriguez PC, Toque HA, Narayanan SP, Caldwell RB. Arginase: a multi-faceted enzyme important in health and disease. Physiol Rev. 2018;98:641–65.

35. Vockley JG, Jenkins CP, Shulka H, Kem RM, Grody WW, Cederbaum SD. Cloning and characterization of the human type II arginase gene. Genomics. 1996;38:118–23.

36. Caldwell RB, Toque HA, Narayanan SP, Caldwell RW. Arginase: an old enzyme with new tricks. Trends Pharmacol Sci. 2015;36:395–405.

37. Yang Z, Ming XF. Functions of arginase isoforms in macrophage inflammatory responses: impact on cardiovascular diseases and metabolic disorders. Front Immunol. 2014;5:533.

38. Hochstedler CM, Leidinger MR, Maher-Sturm MT, Gibson-Corley KN, Meyerholz DK. Immunohistochemical detection of arginase-I expression in formalin-fixed lung and other tissues. J Histotechnol. 2013;36:128–34.

39. Choi S, Park C, Ahn M, Lee JH, Shin T. Immunohistochemical study of arginase 1 and 2 in various tissues of rats. Acta Histochem. 2012;114:487–94.

40. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1–17.

41. Kusano T, Berberich T, Tateda C, Takahashi Y. Polymamines: essential factors for growth and survival. Planta. 2008;228:367–81.

42. Morris SM. Recent advances in arginine metabolism: roles and regulation of the arginases. Brit J Pharm. 2009;157:922–30.

43. Forstemann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829837.

44. Gambardella J, Khondkar W, Morelli MB, Wang X, Santulli G, Trimarco V. Arginine analogues and metabolites modulate myocardial contractility by a nitric oxide synthase 1-dependent mechanism. Circ Res. 2012;110:484–96.

45. Settgeren M, Bohm F, Malstrom RE, Channon KM, Pernow J. L-arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease. Atherosclerosis. 2009;204:73–8.

46. Yan J, Tie G, Messina LM. Tetrahydrobiopterin, L-arginine and vitamin C act synergistically to decrease oxidant stress and increase nitric oxide that increases coronary blood flow recovery after hindlimb ischemia in the rat. Mol Med. 2012;18:1221–30.

47. Rattazzi M, Donato M, Bertacco E, Millonii R, Franchin C, Mortarino C, et al. L-Arginine prevents inflammatory and pro-calcific differentiation of interstitial aortic valve cells. Atherosclerosis. 2020;298:27–35.

48. Lind L, Larsson A, Teerlink T. L-Arginine is related to endothelium-dependent vasodilation in resistance and conduit arteries in divergent ways—the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Atherosclerosis. 2009;203:544–9.

49. Notsu Y, Yano S, Shibata H, Nagai A, Nabika T. Plasma arginine/ADMA ratio as a marker for decreased coronary blood flow in patients with diabetes mellitus and coronary artery disease. Atherosclerosis. 2012;223:582–8.

50. Moser SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1–17.

51. Cho WK, Lee CM, Kang MJ, Huang Y, Giordano FJ, Lee PJ, et al. IL-13 receptor alpha2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2010;298:L600–6.

52. Raffinsson A, Matic LP, Lengquist M, Mahdi A, Shemyakin A, Paulsson-Berne G, et al. L-Arginine-1 increases expression and activity of arginase 2 via ETB receptors and is co-expressed with arginase 2 in human atherosclerotic plaques. Atherosclerosis. 2020;292:215–23.

53. Ryoo S, Shuin A, Chang FM, Shoukas A, Berkowitz DE, Romer LH. OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. Atherosclerosis. 2012;214:279–87.

54. Thacker TN, Gambilla V, Riche F, Silacci P, Stergiopolis N, da Silva RF. Regulation of arginase pathway in response to wall shear stress. Atherosclerosis. 2018;287:63–70.

55. Wuz T, Yiu T, Liu C, Xiong Y, Montani JP, Yang Z, et al. Role of p38 mitogen-activated protein kinase in vascular endothelial aging: interaction with Arginase-II and SKI-1 signaling pathway. Aging. 2015;7:70–81.

56. Beleznai T, Feher A, Spielvogel D, Lansman SL, Bagi Z. Arginase I contributes to diminished coronary arterial dilation in patients with diabetes. Am J Physiol Heart Circ Physiol. 2011;300:H1977–83.

57. Shoukas E, Fouda AY, Lemtalsi T, Haigh S, Fulton D, Ibrahim A, et al. Endothelin-1 increases expression and activity of arginase 2 via ETB receptors and is co-expressed with arginase 2 in human atherosclerotic plaques. Atherosclerosis. 2020;292:215–23.

58. Rojas M, Lemtalsi T, Toque HA, Xu ZM, Fulton D, Caldwell RW, et al. NOX2-induced activation of arginase and diabetes-induced retinal endothelial cell senescence. Antioxidants. 2017;6:43.

59. Tobey IT, Chicoine LG, Cui H, Chen B, Nelin LD. Hypoxygen-induced proliferation of human pulmonary microvascular endothelial cells depends on epidermal growth factor receptor tyrosine kinase activation. Am J Physiol Lung Cell Mol Physiol. 2010;298:L600–6.

60. Am J Physiol Heart Circ Physiol. 2011;300:H1977–83.

61. Am J Physiol Cell Physiol. 2000;279:C248–56.

62. Am J Respir Cell Mol Biol. 2011;45:112–24.
62. Byun HQ, Lee YK, Kim JM, Yoon G. From cell senescence to age-related diseases: differential mechanisms of action of senescence-associated secretory phenotypes (vol 48, pg S59, 2015). BMB Rep. 2016;49:641–50.

63. Shakeri H, Lemmens K, Gevaert AB, De Meyer GRY, Segers VFM. Cellular senescence links aging and diabetes in cardiovascular disease. Am J Physiol-Heart C. 2018;315:H1448–H1462.

64. Kooi ME, Van Meer, Li D, Minhas KM, Cermetaich A, Kim S, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation. 2003;108:2000–6.

65. Garate-Carrillo A, Navarrete-Yanez V, Ortiz-Vilchis P, Guevara G, Castillo C, Mendoza-Lorenzo P, et al. Arginase inhibition by (−)-Epicatechin reverses endothelial cell aging. Eur J Pharm. 2020;885:173442.

66. Tsuboi T, Maeda H, Hayashi T. Administration of L-arginine plus L-citrulline or L-citrulline alone successfully retards retinal endothelial senescence. PLoS One. 2018;13:e0192252.

67. Yepuri G, Velagapudi S, Xiong YY, Rajapakse AG, Montani JP, Ming XF, et al. Positive crosstalk between arginase-II and S6K1 in vascular endothelial inflammation and aging. Aging Cell. 2012;11:1005–16.

68. Xiong Y, Yu MF, Yu Y, Montani JP, Ming XF, Yang Z. Long-term exposure to L-arginine accelerates endothelial cell senescence through arginase-II and S6K1 signaling. Aging. 2014;6:369–79.

69. Xiong Y, Yu Y, Montani JP, Yang Z, Ming XF. Arginase-II induces vascular smooth muscle cell senescence and apoptosis through p65Hsc and p53 independently from its L-arginine ureahydrolase activity: implications for atherosclerotic plaque vulnerability. J Am Heart Assoc. 2013;2:e00096.

70. Kim NH, Choi SH, Yi N, Lee TR, Lee AVY, Arginase-2, a mir-1299 target, enhances pigmentation in melanoma by reducing melanosome degradation via senescence-induced autophagy inhibition. Pigment Cell Melanoma Res. 2017;30:521–30.

71. Li FD, Sun XF, Zheng B, Sun KQ, Zhu J, Li C, et al. Arginase II promotes intervertebral disc degeneration through exacerbating senescence and apoptosis caused by oxidative stress and inflammation via the NF-kappa B pathway. Front Cell Dev Biol. 2011;9:738.

72. Xiong Y, Yepuri G, Montani JP, Ming XF, Yang Z. Arginase-II deficiency extends lifespan in mice. Front Physiol. 2017;8:682.

73. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–57.

74. Origo AM, Gustafsson AB. Cell death in the myocardium: my heart won’t go on. JIBMB Life. 2013:36:551–6.

75. Sujwanprad J, Rojas M, Behzadnia MA, Caldwell RW, Caldwell RB. Arginase 2 deficiency prevents oxidative stress and limits hyperoxia-induced retinal vascular degeneration. PLoS One. 2014;9:e110604.

76. Xiong Y, Yepuri G, Necetin S, Montani JP, Ming XF, Yang Z. Arginase-II promotes tumor necrosis factor-alpha release from pancreatic acinar cells causing beta-cell apoptosis in aging. Diabetes. 2017;66:1366–49.

77. Xu S, Lam SK, Cheng PNM, Ho JCM. Recombinant human arginase induces apoptosis through oxidative stress and cell cycle arrest in small cell lung cancer. Cancer Sci. 2018;109:3471–82.

78. Metayer LE, Brown RD, Carlebur S, Burke GAA, Brown GC. Mechanisms of cell death induced by arginine and asparagine in precursor B-cell lymphoblasts. Apoptosis. 2009;14:249–56.

79. Kiwata S, Kikushima M, Homma-Takeda S, Sunmi D, Endo A, Toyama T, et al. Downregulation of arginase II and renal apoptosis by inorganic mercury: overexpression of arginase II reduces its apoptosis. Arch Toxicol. 2008;82:67–73.

80. Talavera MM, Nuthakki S, Cui H, Jin Y, Liu Y, Nelind LD. Immunostimulated arginase II expression in intestinal epithelial cells reduces nitric oxide production and upregulates. Front Cell Dev Biol. 2015;15:515.

81. Takeuchi T, Nakamura H. Cell proliferation and development. Precate. Dev Growth Differ. 2014;56:323.

82. Wang WE, Li L, Xia X, Fu W, Liao Q, Lan C, et al. Dedifferentiation, proliferation, and redifferentification of adult mammalian cardiomyocytes after ischemic injury. Circulation. 2017;136:384–48.

83. Kim NH, Choi SH, Yi N, Lee TR, Lee AVY, Arginase-2, a mir-1299 target, enhances pigmentation in melanoma by reducing melanosome degradation via senescence-induced autophagy inhibition. Pigment Cell Melanoma Res. 2017;30:521–30.

84. Wei LH, Wu G, Morris SM Jr., Ignarro LJ. Elevated arginase I expression in rat aortic smooth muscle cells increases cell proliferation. Proc Natl Acad Sci USA. 2001;98:9260–4.

85. Kooi ME, Van Meer, Li D, Minhas KM, Cermetaich A, Kim S, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation. 2003;108:2000–6.

86. Li H, Meiningler CJ, Kelly KA, Hawker JR, Morris SM, Wu GY. Activities of arginase I and II are limiting for endothelial cell proliferation. Am J Physiol-Reg I. 2002;282:R64–69.
114. Wei SJ, Cheng L, Liang ES, Wang Q, Zhou SN, Xu H, et al. Poly(ADP-ribose) polymerase 1 increases nitric oxide production and attenuates aortic atherosclerosis through downregulation of arginase II. Clin Exp Pharm. 2017;44:114–122.

115. Feig JE, Vengpenny K, Reiser V, Wu CW, Statnikov A, Alferis CF, et al. Regulation of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. PLoS ONE. 2012;7:e39790.

116. Wang XP, Zhang W, Liu XQ, Wang WK, Yan F, Dong WQ, et al. Arginase 1 enhances atherosclerotic plaque stabilization by inhibiting inflammation and promoting smooth muscle cell proliferation. Eur Heart J. 2014;35:911–9.

117. Yi B, Nguyen MC, Won MH, Kim YM, Ryoo S. Arginase inhibitor 2,3,5,4-tetra-hydroxy-stilbene-2-O-beta-D-glucoside activates endothelial nitric oxide synthase and improves vascular function. Planta Med. 2017;83:210–6.

118. Quitter F, Figulla HR, Ferrari M, Pernow J, Jung C. Increased arginase levels in heart failure represent a therapeutic target to rescue microvascular perfusion. Clin Hemorheol Microcirc. 2013;53:475–85.

119. Buttner P, Werner S, Baskal S, Tsikas D, Adams V, Lurz P, et al. Arginase metabolism and nitric oxide turnover in the ZSF1 animal model for heart failure with preserved ejection fraction. Sci Rep. 2021;11:20684.

120. Heusch P, Aker S, Boengler K, Deindl E, van de Sand A, Klein K, et al. Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S-nitrosylation. Am J Physiol Heart Circ Physiol. 2010;299:H446–453.

121. Taya T, Hakuno D, Shiashi Y, Kujiraoka T, Adachi T. Arginase inhibition augments nitric oxide production and facilitates left ventricular systolic function in hyperlipidaemic-induced cardiomyopathy in mice. Physiol Rep. 2014;2:e12130.

122. Kiss A, Tratsiakovich Y, Mahdi A, Yang J, Gonon AT, Pernow J. Effect of arginase inhibition on ischemia-reperfusion injury via regulation of arginase activity and nitric oxide synthase in type 1 diabetes. Diab Vasc Dis Res. 2017;14:236–45.

123. Yang J, Zheng X, Mahdi A, Zhou Z, Tratsiakovich Y, Jiao T, et al. Red blood cells in type 2 diabetes impair cardiac post-ischemic recovery through an arginase-dependent modulation of nitric oxide synthase and reactive oxygen species. JACC Basic Transl Sci. 2019;4:450–63.

124. Kovamees O, Shemyakin A, Pernow J. Effect of arginase inhibition on ischemia-reperfusion injury in patients with coronary artery disease with and without diabetes mellitus. PLoS One. 2014;9:e103260.

125. Cheng H, Lu T, Wang J, Xia Y, Chai X, Zhang M, et al. HuangqiGuizhiWuwu decoction prevents vascular dysfunction in diabetes via inhibition of endothelial arginase I. Front Physiol. 2020;11:2021.

126. Hein TW, Omae T, Xu W, Yoshida A, Kuo L. Role of arginase in selective impairment of endothelium-dependent nitric oxide synthase-mediated dilation of retinal arterioles during early diabetes. Invest Ophthalmol Vis Sci. 2020;61:36.

127. Chandra S, Fulton DJR, Caldwell RB, Caldwell RW, Toque HA. Hyperglycemia-impaired aortic vasorelaxation mediated through arginase elevation: role of stress kinase pathways. Eur J Physiol. 2019;474:26–37.

128. Zhou ZC, Mahdi A, Tratsiakovich Y, Zahoran S, Kovamees O, Nordin F, et al. Erythrocytes from patients with type 2 diabetes induce endothelial dysfunction via arginase I. J Am Coll Cardiol. 2018;72:769–80.

129. Mahdi A, Tengbom J, Alvarsson M, Wernly B, Zhou Z, Pernow J. Red blood cell peroxynitrite causes endothelial dysfunction in type 2 diabetes mellitus via arginase. Cells-Basel. 2020;9:1712.

130. Li X, Zhao W, Peng L, Li Y, Nie S, Yu H, et al. Elevated serum extracellular vesicle arginase 1 in type 2 diabetes mellitus: a cross-sectional study in middle-aged and elderly population. BMC Endocr Disord. 2022;22:62.

131. Zhang HN, Liu J, Qu D, Wang L, Wong CM, Lau CW, et al. Serum exosomes mediate delivery of arginase 1 as a novel mechanism for endothelial dysfunction in diabetes. Proc Natl Acad Sci USA. 2018;115:E6927–E6936.

132. Al-Kuraisy HM, Al-Gareeb AI, Alexiou A, Batha GE. COVID-19 and L-arginine supplementations: yet to find the missed key.Curr Protein Pept Sci. 2022;23:166–9.

133. Derakhshani A, Hemmat N, Asadzadeh Z, Ghaseminia M, Shadbad MA, Jadi-Z. Li et al. Arginase 1 (Arg1) as an up-regulated gene in COVID-19 patients: a promising marker in COVID-19 immunopathy. J Clin Med. 2021;10:1051.

134. Dean MJ, Ochoa JB, Sanchez-Pino MD, Zabaleta J, Garai J, Del Valle L, et al. Severe COVID-19 is characterized by an impaired type I interferon response and elevated levels of arginase producing granulocytic myeloid-derived suppressor cells. Front Immunol. 2021;695972.

135. Durante W. Targeting arginase in COVID-19-induced immunopathology and vasculopathy. Metabolites. 2022;12:240.
Hrabak A, Bajor T, Temesi A. Computer-aided comparison of the inhibition of arginase and nitric oxide synthase in macrophages by amino acids not related to arginine. Comp Biochem Physiol B Biochem Mol Biol. 1996;113:375–81.

Shatanawi A, Momani MS, Al-Aqtash M, Asfar M, El-Kanatoush S. Effectiveness of arginase inhibitors against experimentally induced stroke. Naunyn Schmiedebergs Arch Pharm. 2018;391:603–12.

Gilinsky MA, Polityko YK, Markel AL. Computer-aided comparison of the inhibition of arginase and nitric oxide synthase in macrophages by amino acids not related to arginine. Comp Biochem Physiol B Biochem Mol Biol. 1996;113:375–81.

Das M, Das DK. Resveratrol and cardiovascular health. Mol Asp Med. 2020;31:503–12.

Choi CI, Koo BH, Hong D, Kwon HJ, Hoe KL, Won MH, et al. Resveratrol is an inhibitor contributing to vascular smooth muscle cell vasocostriction via increasing cytosolic calcium. Mol Med Rep. 2019;19:3767–74.

Bordage S, Pham TN, Zedet A, Gugglielmetti AS, Nappey M, Demougeot C, et al. Investigation of mammalian arginase inhibitor properties of natural ubiquitous polyphenols by using an optimized colorimetric microplate assay. Planta Med. 2017;83:647–53.

Nguyen MC, Ryoo S. Intravenous administration of piceatannol, anarginase inhibitor, improves endothelial dysfunction in aged mice. Korean J Physiol Pharmacol. 2017;21:83–90.

Abdelkawy KS, Lack K, Elbarbry F. Pharmacokinetics and pharmacodynamics of promising arginase inhibitors. Eur J Drug Metab Pharmacokinet. 2017;42:355–70.

Ortiz-Vilchis P, Ortiz-Flores M, Pacheco M, Ramirez-Sanchez I, Moreno-Ulloa A, Vega L, et al. The cardioprotective effects of (−)-Epicatechin are mediated through arginase activity inhibition in a murine model of ischemia/reperfusion. Eur J Pharm. 2018;818:335–42.

Clemente GS, van Waarde A, Antunes IF, Domling A, Elsinga PH. Arginase as a potential biomarker of disease progression: a molecular imaging perspective. Int J Mol Sci. 2020;21:5291.

Vaccines and the cardiovascular system. Hellenic J Cardiol. 2020;61:233–40.

Influenza vaccines and the cardiovascular system. Hellenic J Cardiol. 2020;61:233–40.